PHMB PharmaCom BioVet Inc (CE)

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce the company has located initial commercial sites throughout the United States to begin the full scale build out of the nation's first branded dedicated Veterinary Oncology Treatment Centers.

These initial centers will be located in Houston, Texas, Kansas City, Missouri and Greenwich, Connecticut. These centers are going to provide companion animals with cancer treatment using licensed proprietary technologies.

According to Sharon Berthold, Executive Vice President of PharmaCom BioVet, Inc., "These key targeted markets were chosen based on the large populations of the cities themselves as well as the cities' large surrounding populations. PharmaCom BioVet, Inc. will begin a targeted marketing campaign marketing its services to non-oncology specialized veterinarians in these cities and surrounding areas using a specialized sales force. Local Television commercials will also be filmed and aired on local cable television in these targeted markets."

About Us:

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized veterinary oncology treatment centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer greater life expectancy and decreased suffering.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact: Investor Relations 919-572-6395 investors@pharmacombiovet.com